

Inhibition of SIV/SMM Replication In Vitro by CD8⁺ Cells From SIV/SMM Infected Seropositive Clinically Asymptomatic Sooty Mangabeys

Jonathan D. Powell,¹ Tamar Yehuda-Cohen,¹ Francois Villinger,^{1,2} Harold M. McClure,^{1,2} Kenneth W. Sell,² Aftab Ahmed-Ansari^{1,2}

¹*Department of Pathology and Laboratory Medicine, Winship Cancer Center, and* ²*Division of Pathobiology and Immunobiology, Yerkes Regional Primate Research Center, Emory University, Atlanta, GA, USA*

Several investigators have demonstrated the ability of CD8⁺ T cells from HIV-1 infected humans and SIV infected rhesus macaques to inhibit viral replication in vitro. In this report we show that CD8⁺ cells from naturally SIV infected sooty mangabeys also have the ability to inhibit viral replication in vitro. In addition, initial experiments which seek to elucidate the mechanism and antigen specificity of CD8-mediated suppression are described.

Key words: CD8⁺ T cells • Viral replication • AIDS

INTRODUCTION

Cell-mediated immunity (CMI) in the form of virus-specific MHC-restricted CD8⁺ cytotoxic T cells (CTLs) has been shown to play a major role in antiviral immunity [2,25]. In the murine influenza model, adoptive transfer of influenza nucleoprotein (NP) specific CTLs has been shown not only to reduce the replication of the virus in the respiratory tract of mice [8,9,21] but also to protect these mice from lethal influenza infection [16]. In addition to CD8⁺ T cell clones, natural killer cells (NK) and lymphokine activated killer cells (LAK) also play a role in host defenses against viral infection [5,12,17]. The role of CMI in human infection with HIV-1 is far

Accepted for publication January 24, 1990.

from clear. Some studies have shown the presence of HIV-specific CTLs in the peripheral blood mononuclear cells (PBMC) of patients with AIDS [13,19] and in chimpanzees experimentally immunized with recombinant HIV-1 [23,24]. Other studies have shown the presence of CMI in the form of autoimmunity [10]. Several investigations have demonstrated the ability of CD8⁺ cells from HIV-1 infected individuals [20] and SIV infected rhesus macaques [6] to regulate HIV-1 and SIV replication in autologous cells in vitro. Currently, it is unclear whether this regulation is due to cytotoxic mechanisms or conventional suppressor T cell mechanisms.

Our laboratory has carried out studies designed to elucidate natural and acquired CMI in both sooty mangabeys (*Cercocebus atys*), a great majority (> 75%) of which are naturally infected with SIV/SMM but remain clinically asymptomatic, and rhesus macaques (*Macaca mulatta*), which, when experimentally infected with SIV/SMM, die of an AIDS-like disease similar to that seen in humans infected with HIV-1 [4,11]. Elucidation of differences in the natural and antigen-specific acquired immunity in these two species may provide important clues to the mechanisms of pathogenesis. Our initial studies demonstrated that PBMC of sooty mangabeys, when compared to rhesus macaques, have a higher frequency of CD8⁺ T cells which appear to be activated since a high proportion express HLA Class II molecules [1]. Further, in the mangabey it is the CD8⁺ T cells that mediate NK cell and LAK cell activity [11,14]. In light of the findings that CD8⁺ cells from SIV infected macaques and HIV-1 infected humans have the ability to inhibit viral replication in vitro, and the prominence of CD8⁺ cells in the PBMC of naturally infected sooty mangabeys, we wanted to determine whether CD8⁺ cells from sooty mangabeys have the ability to inhibit viral replication in vitro. It was reasoned that since SIV infection in rhesus and HIV-1 infection in humans usually leads to death, the finding of CD8-mediated viral suppression in the naturally infected yet clinically asymptomatic mangabeys might help in the effort to delineate pathogenic immunity from protective immunity.

MATERIALS AND METHODS

Animals

Adult rhesus macaques and sooty mangabeys housed at the Yerkes Regional Primate Research Center (YRPRC) were the source of blood samples for this study. Rhesus macaques were experimentally injected with 10⁴ TCID of SIV/SMM as previously described [1] while the seropositive mangabeys used in this study were all naturally infected with SIV.

Isolation of Lymphocytes and CD8 Depletion

PBMC were isolated using a 60% Percoll gradient as previously described [1]. They were washed twice in media, counted, and adjusted to a concentration of 2×10^6 /ml. PHA-P(Gibco, Grand Island, NY) at a final concentration of 0.2% was added to cell cultures which were incubated at 37°C in a 7% CO₂ humidified atmosphere for three days. The cells were then washed twice, and aliquots of the cells were depleted of CD8⁺ T cells, using a biomagnetic separation system [22]. In brief, 10^7 lymphocytes were incubated with 100 μ l of Leu-2a (anti CD8, Becton-Dickinson, Mountain View, CA) on ice for 40 minutes. Excess antibody was removed by washing the cells in media. The media was then aspirated, and the cells were next incubated with 2 ml of goat anti mouse Ig conjugated beads (Collaborative Research, Medford, MA) for 40 minutes on ice. CD8⁺ cells were depleted by placing the lymphocytes in a magnetic field.

CD8 Suppression of Reverse Transcriptase (RT) Activity

Whole PHA blasts and CD8 depleted PHA blasts (as prepared above) were adjusted to a concentration of 10^6 cells/ml in a volume of 2 ml of media containing 10 units/ml rIL-2. For some experiments 20 μ l of $100 \times$ SIV/SMM grown in the HTC cell line and prepared commercially (Advanced Biotechnologies, Silver Spring, MD) was added to the culture tubes. The cultures were maintained at 37°C in a 7% CO₂ humidified atmosphere, and supernatant fluid was harvested every four days and replenished. RT activity of the supernatant fluid was assessed as previously described by Spira et al. [15].

FEC1 Cell Line

The FEC1 cell line is an EBV transformed B cell line prepared in our laboratory from a seropositive sooty mangabey. This line was established by immortalizing B cells from the PBMC of the sooty mangabey (FEc) by incubation with a preparation of EBV produced from the B95-8 cell line (ATCC, Rockville, MD). For the first ten tissue culture passages, these EBV transformed mangabey cells produced anti-SIV antibodies; however, antibody production by these cells has since ceased. The cells were CD4 transfected with the gene that codes for the human CD4 molecule and with a neomycin resistance gene, using a Moloney virus vector kindly provided by Dr. Richard Morgan, NIH, NHLBI. Selection for cells in which the CD4 gene was integrated was accomplished by placing the cells in media containing neomycin. Expression of CD4 was confirmed by flow microfluorometric (FMF) analysis, using fluorescein conjugated Leu-3a.

CD8 suppression of RT in the FEc1 cell line was performed as follows. To 0.5×10^6 FEc1 cells were added 2×10^6 PHA blasts prepared from the PBMC from the mangabey (Fec). The cultures were maintained in a final volume of 2 ml of media containing 10 units/ml rIL-2. On day zero, 20 μ l of SIV/SMM or 100 μ l of $10 \times$ HIV-2 (courtesy of NIH, AIDS Research and Reference Reagent Program) was added to each culture; on day 2 the cultures were centrifuged, and the supernatant fluid was removed and replaced in order to remove any excess virus. On day 7 the supernatant fluids were harvested for RT activity.

Media

The media used throughout was RPMI 1640 supplemented with 100 units/ml of penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine, and 10% fetal bovine serum (all from Gibco, Grand Island, NY). rIL-2 was a kind gift from Hoffman LaRoche Laboratories (Nutley, NJ).

RESULTS

CD8-Mediated Suppression of RT Activity

The ability of CD8⁺ cells from SIV-infected rhesus macaques to inhibit the replication of exogenously added SIV in vitro was previously demonstrated [6]. As seen in Figure 1, we have been able to reproduce these results in that CD8⁺ cells from the SIV/SMM infected rhesus were able to clearly inhibit the replication of the exogenously added SIV/SMM. Likewise, the CD8⁺ cells from the uninfected rhesus were not able to suppress viral replication. Furthermore, as shown in Figure 1, the CD8⁺ cells from the seropositive mangabey were also able to inhibit the replication of SIV. Thus, CD8⁺ T cells from the chronically infected yet asymptomatic sooty mangabeys have the ability to inhibit RT activity in vitro.

SIV is easily isolated in vitro from cells derived from sooty mangabeys. Normally, this is accomplished by co-culturing these mangabey cells with human PHA blasts. It is possible that these xenogeneic cultures may abrogate CD8-mediated suppression of viral replication. We wanted to determine if CD8⁺ cells were able to inhibit the replication of endogenous virus found in the PBMC of mangabeys. Thus, we measured endogenous RT activity in mangabey PBMC in the absence of human cells. Figure 2, which shows the results of one such experiment, is representative of data from four additional experiments. Whole PHA blasts or CD8 depleted PHA blasts were cultured as described in the Materials and Methods section; however, in this case, no




Fig. 1. Inhibition of RT activity by CD8⁺ cells. PBMC from a seropositive mangabey were cultured in the presence of 0.2% PHA for three days. An aliquot of cells from each of these cultures was CD8 depleted. Exogenous SIV/SMM was added to each of the samples and cultured for 21 days. RT activity was monitored every four days. The data is expressed as the mean of triplicate cultures \pm SD.

exogenous virus was added to the culture. As seen in Figure 2, the RT activity was higher in the cultures which were CD8 depleted, indicating that mangabey CD8⁺ T cells have the ability to inhibit the replication of virus which is found endogenously in the PBMC of mangabeys.

CD8-Mediated Suppression of Viral Replication in an EBV Transformed CD4 Expressing Cell Line

The fact that CD8⁺ cells from infected sooty mangabeys have the ability to inhibit viral replication suggests that perhaps this immune mechanism may play an important role in vivo. Since the mangabeys remain chronically infected with SIV, they provide a unique opportunity to study the mechanisms behind this phenomenon. EBV transformed B cells from an SIV infected mangabey were established in our laboratory. These cells were trans-




Fig. 2. Inhibition of endogenous virus replication by mangabey CD8⁺ cells. PBMC from a seropositive mangabey were cultured in the presence of 0.2% PHA for three days. An aliquot of cells from this culture was CD8 depleted. RT activity from the whole PBMC culture and the CD8 depleted culture was monitored on days 7, 12, and 17. The data shown is representative of four additional experiments performed at the same time.

fects with the human CD4 gene. The detailed characterization of these cells is currently in progress. Figure 3 shows that these cells are expressing the CD4 molecule on their surface. Although it appears that most of the cells are expressing the CD4 gene, the overall mean density of expression of this cell surface marker is low. Currently, we are in the process of subcloning these cells in order to isolate a high density CD4 expressing clone. Nonetheless, as seen in Figure 4, these cells are able to replicate both SIV and HIV-2. Furthermore, the addition of autologous CD8⁺ cells inhibits not only SIV/SMM but also HIV-2 replication in this cell line. This suggests that the epitopes involved in the recognition of the target cells for CD8-mediated suppression are shared by both SIV and HIV-2 infected cells. In light of the genomic homology between HIV-2 and SIV at the DNA level, these data are not surprising [3]. In the future we hope to exploit this autologous CD4⁺ cell




Fig. 3. Expression of CD4 on the surface of the FcE1 cell line. FcE1 cells were incubated with either fluoresceinated goat anti mouse Ig (A) or fluoresceinated Leu-3a (B) and analyzed by FCM. Although the density of the CD4 molecule on the surface of the cells is low, the entire peak in B appears to shift to the right (as compared with the negative control in A), indicating expression of CD4 on most of the cells.

line in order to further characterize the antigen specificity and mechanism of CD8-mediated suppression and investigate CTL activity in SIV infected mangabeys.

DISCUSSION

CD8-mediated suppression of viral replication in HIV-infected human subjects, as well as SIV-infected rhesus macaques, has previously been demonstrated [6,22]; however, the importance of this mechanism is tempered by the fact that infected human subjects and rhesus monkeys invariably die of AIDS. Mangabeys, on the other hand, are chronically infected with SIV, without any clinical consequences. Thus, the finding that CD8⁺ cells from mangabeys can inhibit viral replication suggests that perhaps there is some *in vivo* relevance to these findings. This is particularly true since we have previously documented the prominent role of CD8⁺ cells in the immune system of sooty mangabeys [11,14]. In addition, the *in vivo* frequency of circulating CD8⁺ cells in the PBMC of a majority of rhesus or pigtailed macaques experimentally infected with SIV/SMM drops precipitously prior to the death of the animals. The mechanisms behind the abrogation of CD8-mediated immunity in rhesus and humans have yet to be elucidated. Certainly, it is not inconceivable that autoimmunity may play a role in such a




Fig. 4. Inhibition of SIV/SMM and HIV-2 replication in FEC1 cells by autologous CD8⁺ cells. PBMC from the seropositive mangabey FEC were cultured in the presence of 0.2% PHA for three days. Aliquots of these cells were added to cultures containing FEC1 cells and either HIV-2 or SIV/SMM. RT activity was determined after seven days in culture. The data is expressed as the mean of triplicate cultures \pm SD.

process. Indeed, antilymphocyte antibodies in the serum of AIDS patients have been described [7]. If such is the case, however, then how do mangabeys avoid such a fate? Perhaps it is the chronicity of the natural infection of SIV in mangabeys that leads to the development of tolerance to the autoimmune-producing viral epitopes. Mangabeys may actually acquire SIV infection at or before birth, which would lead to tolerance.

The specificity and molecular mechanisms of CD8-mediated suppression of viral replication have yet to be elucidated. To address this issue, our laboratory has established an EBV transformed cell line from an SIV infected mangabey in our colony. The transfection of these cells with the human CD4 gene makes available an autologous cell line which is SIV/SMM replication-competent. It is reasoned that Fec1 cell line or similar strategies will help to dissect the mechanism involved in this phenomenon. The data presented in this report show that autologous CD8⁺ cells are able to inhibit the replication

of SIV in these cells. Furthermore, the antigen specificity of CD8-mediated suppression extends to HIV-2. Currently, experiments are in progress to test whether this antigen crossreactivity also holds true for the evolutionarily more distant HIV-1. In addition, we plan to use the FEc1 cell line to examine the role of CD8⁺ cells on viral regulatory molecules. That is, do CD8⁺ cells mediate suppression at the level of the induction of virus replication?

Phenotypic data may indicate that CD8-mediated suppression is classical CTL activity [18]. In the mangabey, NK and LAK activity is mediated by cells that do not express conventional NK and LAK cell surface markers [14]. Thus, we do not rule out the possibility that immunosurveillance may be involved. It may be that mangabeys have developed an immunosurveillance system which relies more heavily on a population of NK cells (which are normally found to a lesser extent in humans and rhesus macaques). Infection with HIV and SIV may enhance the frequency of these cells, which, in addition to exhibiting conventional NK activity, are able to inhibit viral replication. This might explain the high frequency of activated CD8⁺ cells in the PBMC of mangabeys. The possibility that CTL activity is the basis of this inhibition of virus replication *in vitro* is certainly important to consider and is being actively pursued in our laboratory. Attempts are also being made to use the SIV infected FEc1 cell line to measure SIV-specific CTL and CMI in the PBMC of the sooty mangabey, FEc.

ACKNOWLEDGMENTS

The authors thank Professor Thomas Gordon and Dr. Daniel Anderson, YRPRC, for collection of animal blood samples, Ms. Ann Mayne and Mr. Matthew Vuchetich for technical assistance, and Hoffman LaRoche for recombinant human IL-2. Supported by USPHS grants NIH-R01-AI-27057-02 and NIH-DRR-00165.

REFERENCES

1. Ahmed-Ansari A, Brodie AR, Fultz PN, Anderson DC, Sell KW, McClure HM: Flow microfluorometric analysis of peripheral blood mononuclear cells from nonhuman primates: Correlation of phenotype with immune function. *Am J Primatol* 17:107-131, 1989.
2. Berke G: Cytotoxic T lymphocytes. How do they function? *Immunol Rev* 72:5-42, 1983.
3. Chakrabarti L, Guyader M, Alizon M, Daniel MK, Derosiens RC, Tiollais P, Sonigo P: Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. *Nature* 328:543-544, 1987.
4. Fultz PN, McClure HM, Anderson DC, Swenson RB, Anand R, Srinivasan A: Isolation of

- a T lymphotropic retrovirus from naturally infected sooty mangabey monkeys (*Cercocebus atys*). Proc Natl Acad Sci USA 83:5289-5290, 1986.
5. Herberman RB, Ortaldo JR: Natural killer cells: Their role in defense against disease. Science 214:24-26, 1984.
 6. Kannagi M, Chalifoux LV, Lord CE, Letvin NL: Suppression of simian immunodeficiency virus replication *in vitro* by CD8⁺ lymphocytes. J Immunol 140:2237-2242, 1988.
 7. Kiprov DD, Anderson RE, McCord PR: Antilymphocyte antibodies and seropositivity for retroviruses in groups at high risk for AIDS. N Engl J Med 312:1517-1519, 1985.
 8. Lui Y, Askonas BA: Biological properties of an influenza A virus specific killer T cell clone: Inhibition of virus replication *in vivo* and induction of delayed-type hypersensitivity reactions. J Exp Med 154:225-234, 1981.
 9. Lukacher AE, Braciale V, Braciale TJ: *In vivo* effector function of influenza virus specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 160:814-826, 1984.
 10. Lysterly HK, Mathews TJ, Langlois AJ, Bolognesi DP, Weinhold KJ: Human T cell lymphotropic virus IIIB glycoprotein bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA 84:4601-4605, 1987.
 11. McClure HM, Anderson DC, Fultz PN, Ansari AA, Lockwood E, Brodie AR: Spectrum of disease in macaque monkeys chronically infected with SIV/SMM. Vet Immunol Immunopathol 21:13-24, 1989.
 12. Ortaldo Jr, Herberman RB: Heterogeneity of natural killer cells. Ann Rev Immunol 2:359-394, 1984.
 13. Plata F, Autran B, Pedroza-Martins L, Wain-Hobson S, Raphael M, Mayaud C, Denis M, Guillon SM, Dehre P: AIDS virus-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:348-351, 1987.
 14. Powell JD, McClure HM, Anderson DC, Fultz PN, Sell KW, Ahmed-Ansari A: Phenotypic and functional differences in NK and LAK cells in the peripheral blood of sooty mangabeys and rhesus macaques. Cell Immunol 124:107-118, 1989.
 15. Spira TJ, Bozeman LH, Holman RC, Warfield DT, Phillips SK, Feorino PM: Micromethod for assaying reverse transcriptase of human T cell lymphotropic virus Type III/LAV. J Clin Microbiol 25:97-99, 1987.
 16. Taylor PM, Askonas BA: Influenza nucleoprotein-specific cytotoxic T cell clones are protective *in vivo*. Immunology 58:417-420, 1986.
 17. Trinchieri G, Perussia B: Human natural killer cells: Biologic and pathologic aspects. Lab Invest 50:489-513, 1984.
 18. Tsubota H, Lord CE, Watkins DE, Morimoto C, Letvin NL: A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med 169:1421-1434, 1989.
 19. Walker BD, Chakrabarti L, Moss B, Paradis TJ, Hirsch MS, Schooley RJ: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:245-248, 1987.
 20. Walker CM, Moody DJ, Stites DP, Levy JA: CD8⁺ lymphocytes can control HIV infection *in vitro* by suppressing virus replication. Science 234:1563-1566, 1986.
 21. Wells MA, Ennis FA, Albrecht P: Recovery from a viral respiratory infection II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol 126:1042-1046, 1981.
 22. Whitesides GW, Kazlauskas RJ, Josephson L: Magnetic separations in biotechnology. Trends in Biotechnol 1:144-148, 1983.
 23. Zarling JM, Morton W, Moran PA, McClure J, Kosowski SG, Hu S: T cell responses to

human AIDS virus in macaques immunized with recombinant vaccinia viruses. *Nature* 323:344-346, 1986.

24. Zarling JM, Eichberg JW, Moran PA, McClure J, Sridhar P, Hu S-L: Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. *J Immunol* 139:988-990, 1987.
25. Zinkernagel RM, Doherty PC: MHC restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T cell restrictions, specificity, function, and responsiveness. *Adv Immunol* 27:51-177, 1979.

Dr. Aftab Ahmed-Ansari, Emory University School of Medicine, Winship Cancer Center, Room 5008, 1327 Clifton Road, N.E., Atlanta, GA 30322